Immune Cell Interplay in Colorectal Cancer Prognosis

World Journal of Gastrointestinal Oncology

Volumn 7, Issue 10, 2015, Pages 221-232

  Norton, Samuel E ^a   Ward Hartstonge, Kirsten A ^a   Taylor, Edward S ^a   Kemp, Roslyn A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Colorectal cancer neoplasms; Fibroblasts; Immune system processes; Macrophages; T lymphocytes

Indexed keywords

EID: 85015708751     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v7.i10.221     Document Type: Article

References (105)

1. 1 Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers EJ. Colorectal cancer screening: a global overview of existing programmes. Gut 2015; 64: 1637-1649 [PMID: 26041752 DOI: 10.1136/gutjnl-2014-309086]
2. 2 Hölzel M, Bovier A, Tüting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013; 13: 365-376 [PMID: 23535846 DOI: 10.1038/nrc3498]
3. 3 Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012; 336: 1268-1273 [PMID: 22674334 DOI: 10.1126/science.1223490]
4. 4 Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O’Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D’Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205 [PMID: 23034130 DOI: 10.1186/1479-5876-10-205]
5. 5 Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896 [PMID: 20856220 DOI: 10.1038/ni.1937]
6. 6 Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, Laghi L, Allavena P, Mantovani A, Marchesi F. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res 2014; 20: 2147-2158 [PMID: 24523438 DOI: 10.1158/1078-0432.CCR-13-2590]
7. 7 Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013; 2: e25961 [PMID: 24083084 DOI: 10.4161/onci.25961]
8. 8 Djaldetti M, Bessler H. Modulators affecting the immune dialogue between human immune and colon cancer cells. World J Gastrointest Oncol 2014; 6: 129-138 [PMID: 24834143 DOI: 10.4251/wjgo.v6.i5.129]
9. 9 Antoniou E, Margonis GA, Angelou A, Zografos GC, Pikoulis E. Cytokine networks in animal models of colitis-associated cancer. Anticancer Res 2015; 35: 19-24 [PMID: 25550530]
10. 10 Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 2011; 4: 53-61 [PMID: 21673876]
11. 11 Chattopadhyay PK, Gierahn TM, Roederer M, Love JC. Singlecell technologies for monitoring immune systems. Nat Immunol 2014; 15: 128-135 [PMID: 24448570 DOI: 10.1038/ni.2796]
12. 12 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med 2014; 211: 1503-1523 [PMID: 25071162 DOI: 10.1084/jem.20140692]
13. 13 Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, Banerjee D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68: 4331-4339 [PMID: 18519693 DOI: 10.1158/0008-5472.CAN-08-0943]
14. 14 Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 2009; 4: e7475 [PMID: 19834619 DOI: 10.1371/journal.pone.0007475]
15. 15 Madar S, Goldstein I, Rotter V. ‘Cancer associated fibroblasts’—more than meets the eye. Trends Mol Med 2013; 19: 447-453 [PMID: 23769623 DOI: 10.1016/j.molmed.2013.05.004]
16. 16 Herrera M, Islam AB, Herrera A, Martín P, García V, Silva J, Garcia JM, Salas C, Casal I, de Herreros AG, Bonilla F, Peña C. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res 2013; 19: 5914-5926 [PMID: 24052018 DOI: 10.1158/1078-0432.CCR-13-0694]
17. 17 Tommelein J, Verset L, Boterberg T, Demetter P, Bracke M, De Wever O. Cancer-associated fibroblasts connect metastasispromoting communication in colorectal cancer. Front Oncol 2015; 5: 63 [PMID: 25853091 DOI: 10.3389/fonc.2015.00063]
18. 18 Knüpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients—a summary of published results. Int J Colorectal Dis 2010; 25: 135-140 [PMID: 19898853 DOI: 10.1007/s00384-009-0818-8]
19. 19 Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003; 97: 960-968 [PMID: 12569594 DOI: 10.1002/cncr.11152]
20. 20 Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumorinfiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002; 62: 7042-7049 [PMID: 12460925]
21. 21 Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumourstroma interaction. Br J Cancer 2014; 110: 469-478 [PMID: 24346288 DOI: 10.1038/bjc.2013.748]
22. 22 Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011; 140: 799-808, quiz e11 [PMID: 21115010 DOI: 10.1053/j.gastro.2010.11.041]
23. 23 Koshida Y, Kuranami M, Watanabe M. Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor. J Surg Res 2006; 134: 270-277 [PMID: 16600304 DOI: 10.1016/j.jss.2006.02.025]
24. 24 Torres S, Bartolomé RA, Mendes M, Barderas R, Fernandez-Aceñero MJ, Peláez-García A, Peña C, Lopez-Lucendo M, Villar-Vázquez R, de Herreros AG, Bonilla F, Casal JI. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res 2013; 19: 6006-6019 [PMID: 24025712 DOI: 10.1158/1078-0432.CCR-13-1130]
25. 25 Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899 [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025]
26. 26 Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA, Sukhdeo K, DeVecchio J, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich JN. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 2013; 210: 2851-2872 [PMID: 24323355 DOI: 10.1084/jem.20131195]
27. 27 Schellerer VS, Langheinrich M, Hohenberger W, Croner RS, Merkel S, Rau TT, Stürzl M, Naschberger E. Tumor-associated fibroblasts isolated from colorectal cancer tissues exhibit increased ICAM-1 expression and affinity for monocytes. Oncol Rep 2014; 31: 255-261 [PMID: 24253852 DOI: 10.3892/or.2013.2860]
28. 28 Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104: 2224-2234 [PMID: 15231578 DOI: 10.1182/blood-2004-03-1109]
29. 29 Silzle T, Kreutz M, Dobler MA, Brockhoff G, Knuechel R, Kunz-Schughart LA. Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol 2003; 33: 1311-1320 [PMID: 12731056 DOI: 10.1002/eji.200323057]
30. 30 Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012; 7: e50946 [PMID: 23284651 DOI: 10.1371/journal.pone.0050946]
31. 31 Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol 2013; 14: 986-995 [PMID: 24048120 DOI: 10.1038/ni.2705]
32. 32 Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol 2014; 14: 392-404 [PMID: 24854589 DOI: 10.1038/nri3671]
33. 33 Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41: 14-20 [PMID: 25035950 DOI: 10.1016/j.immuni.2014.06.008]
34. 34 Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, Hussell T, Feldmann M, Udalova IA. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011; 12: 231-238 [PMID: 21240265 DOI: 10.1038/ni.1990]
35. 35 Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007; 13: 1472-1479 [PMID: 17332291 DOI: 10.1158/1078-0432.CCR-06-2073]
36. 36 Kang JC, Chen JS, Lee CH, Chang JJ, Shieh YS. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol 2010; 102: 242-248 [PMID: 20740582 DOI: 10.1002/jso.21617]
37. 37 Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O, Guilliams M, Malissen B, Agace WW, Mowat AM. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol 2013; 6: 498-510 [PMID: 22990622 DOI: 10.1038/mi.2012.89]
38. 38 Smith PD, Smythies LE, Shen R, Greenwell-Wild T, Gliozzi M, Wahl SM. Intestinal macrophages and response to microbial encroachment. Mucosal Immunol 2011; 4: 31-42 [PMID: 20962772 DOI: 10.1038/mi.2010.66]
39. 39 Zigmond E, Jung S. Intestinal macrophages: well educated exceptions from the rule. Trends Immunol 2013; 34: 162-168 [PMID: 23477922 DOI: 10.1016/j.it.2013.02.001]
40. 40 Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-265 [PMID: 11857487 DOI: 10.1002/path.1027]
41. 41 Obeid E, Nanda R, Fu YX, Olopade OI. The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol 2013; 43: 5-12 [PMID: 23673510 DOI: 10.3892/ijo.2013.1938]
42. 42 Erreni M, Mantovani A, Allavena P. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron 2011; 4: 141-154 [PMID: 21909876 DOI: 10.1007/s12307-010-0052-5]
43. 43 Xu H, Lai W, Zhang Y, Liu L, Luo X, Zeng Y, Wu H, Lan Q, Chu Z. Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer 2014; 14: 330 [PMID: 24885636 DOI: 10.1186/1471-2407-14-330]
44. 44 Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY. Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Hum Immunol 2009; 70: 151-158 [PMID: 19272324 DOI: 10.1016/j.humimm.2009.01.004]
45. 45 Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Danø K, Nielsen BS. MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 2006; 4: 293-302 [PMID: 16687484 DOI: 10.1158/1541-7786.MCR-06-0003]
46. 46 Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol 2004; 172: 4630-4636 [PMID: 15034082]
47. 47 Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, Ogino S. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011; 17: 1452-1462 [PMID: 21310826 DOI: 10.1158/1078-0432.CCR-10-2694]
48. 48 Tripathi C, Tewari BN, Kanchan RK, Baghel KS, Nautiyal N, Shrivastava R, Kaur H, Bhatt ML, Bhadauria S. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 2014; 5: 5350-5368 [PMID: 25051364]
49. 49 Shay JE, Imtiyaz HZ, Sivanand S, Durham AC, Skuli N, Hsu S, Mucaj V, Eisinger-Mathason TS, Krock BL, Giannoukos DN, Simon MC. Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer. Carcinogenesis 2014; 35: 1067-1077 [PMID: 24408928 DOI: 10.1093/carcin/bgu004]
50. 50 Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, Lewis CE. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxiaregulated gene therapy. Am J Pathol 2003; 163: 1233-1243 [PMID: 14507633 DOI: 10.1016/S0002-9440(10)63483-9]
51. 51 Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester MA, Macintyre AN, Goraksha-Hicks P, Rathmell JC, Makowski L. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem 2014; 289: 7884-7896 [PMID: 24492615 DOI: 10.1074/jbc.M113.522037]
52. 52 Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-258 [PMID: 23034650 DOI: 10.1038/nature11465]
53. 53 Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 338: 120-123 [PMID: 22903521 DOI: 10.1126/science.1224820]
54. 54 Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011; 407: 348-354 [PMID: 21396350 DOI: 10.1016/j.bbrc.2011.03.021]
55. 55 Ohtani H, Naito Y, Saito K, Nagura H. Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity? Lab Invest 1997; 77: 231-241 [PMID: 9314947]
56. 56 Sugita J, Ohtani H, Mizoi T, Saito K, Shiiba K, Sasaki I, Matsuno S, Yagita H, Miyazawa M, Nagura H. Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions. Jpn J Cancer Res 2002; 93: 320-328 [PMID: 11927015]
57. 57 Edin S, Wikberg ML, Rutegård J, Oldenborg PA, Palmqvist R. Phenotypic skewing of macrophages in vitro by secreted factors from colorectal cancer cells. PLoS One 2013; 8: e74982 [PMID: 24058644 DOI: 10.1371/journal.pone.0074982]
58. 58 Fernando MR, Reyes JL, Iannuzzi J, Leung G, McKay DM. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One 2014; 9: e94188 [PMID: 24736635 DOI: 10.1371/journal.pone.0094188]
59. 59 Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666 [PMID: 16371631 DOI: 10.1056/NEJMoa051424]
60. 60 Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964 [PMID: 17008531 DOI: 10.1126/science.1129139]
61. 61 Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10: 1 [PMID: 22214470 DOI: 10.1186/1479-5876-10-1]
62. 62 Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25: 261-267 [PMID: 23579076 DOI: 10.1016/j.coi.2013.03.004]
63. 63 Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306 [PMID: 22419253 DOI: 10.1038/nrc3245]
64. 64 Diederichsen AC, Hjelmborg Jv, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52: 423-428 [PMID: 12695859 DOI: 10.1007/s00262-003-0388-5]
65. 65 Väyrynen JP, Tuomisto A, Klintrup K, Mäkelä J, Karttunen TJ, Mäkinen MJ. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer 2013; 109: 1839-1847 [PMID: 24008661 DOI: 10.1038/bjc.2013.508]
66. 66 Nagorsen D, Scheibenbogen C, Schaller G, Leigh B, Schmittel A, Letsch A, Thiel E, Keilholz U. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. Int J Cancer 2003; 105: 221-225 [PMID: 12673683 DOI: 10.1002/ijc.11052]
67. 67 Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P, Nummer D, Specht S, Antolovic D, Galindo L, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Weitz J. Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg 2006; 244: 986-992; discussion 992-993 [PMID: 17122624 DOI: 10.1097/01.sla.0000247058.43243.7b]
68. 68 Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, Benner A, Büchler MW, Jäger D, Halama N, Khazaie K, Weitz J, Beckhove P. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest 2015; 125: 739-751 [PMID: 25562322 DOI: 10.1172/JCI74894]
69. 69 Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944-5951 [PMID: 19858404 DOI: 10.1200/JCO.2008.19.6147]
70. 70 Salama P, Phillips M, Platell C, Iacopetta B. Low expression of Granzyme B in colorectal cancer is associated with signs of early metastastic invasion. Histopathology 2011; 59: 207-215 [PMID: 21884199 DOI: 10.1111/j.1365-2559.2011.03915.x]
71. 71 Ong SM, Tan YC, Beretta O, Jiang D, Yeap WH, Tai JJ, Wong WC, Yang H, Schwarz H, Lim KH, Koh PK, Ling KL, Wong SC. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur J Immunol 2012; 42: 89-100 [PMID: 22009685 DOI: 10.1002/eji.201141825]
72. 72 Blaschitz C, Raffatellu M. Th17 cytokines and the gut mucosal barrier. J Clin Immunol 2010; 30: 196-203 [PMID: 20127275 DOI: 10.1007/s10875-010-9368-7]
73. 73 Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-162 [PMID: 21349428 DOI: 10.1016/j.immuni.2011.02.012]
74. 74 Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 2010; 21: 413-423 [PMID: 21074482 DOI:10.1016/j.cytogfr.2010.10.002]
75. 75 Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-1271 [PMID: 21303976 DOI: 10.1158/0008-5472.CAN-10-2907]
76. 76 Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-2627 [PMID: 12411307 DOI: 10.1182/blood-2002-05-1461]
77. 77 Straus DS. TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer 2013; 12: 78 [PMID: 23866118 DOI: 10.1186/1476-4598-12-78]
78. 78 De Simone V, Franzè E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, Monteleone G, Stolfi C. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene 2015; 34: 3493-3503 [PMID: 25174402 DOI: 10.1038/onc.2014.286]
79. 79 Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E, Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-Bonnet G, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 2013; 15: 848-862 [PMID: 23814496]
80. 80 Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev 2014; 259: 88-102 [PMID: 24712461 DOI: 10.1111/imr.12160]
81. 81 Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol 2013; 25: 305-312 [PMID: 24211039 DOI: 10.1016/j.smim.2013.10.009]
82. 82 Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60: 909-918 [PMID: 21644034 DOI: 10.1007/s00262-011-1046-y]
83. 83 Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, Juenger S, Vlodavsky I, Khazaie K, Jaeger D, Reissfelder C, Antolovic D, Aigner M, Koch M, Beckhove P. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119: 3311-3321 [PMID: 19809157 DOI: 10.1172/JCI39608]
84. 84 Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949 [PMID: 15322536 DOI: 10.1038/nm1093]
85. 85 Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, Kumar M, Jones S, Rees B, Williams G, Gallimore A, Godkin A. Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012; 61: 1163-1171 [PMID: 22207629 DOI: 10.1136/gutjnl-2011-300970]
86. 86 Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q, Wang H, Chen J, Wang H. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 2011; 6: e19495 [PMID: 21559338 DOI: 10.1371/journal.pone.0019495]
87. 87 Xu L, Xu W, Qiu S, Xiong S. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol 2010; 135: 466-475 [PMID: 20181533 DOI: 10.1016/j.clim.2010.01.014]
88. 88 Crome SQ, Clive B, Wang AY, Kang CY, Chow V, Yu J, Lai A, Ghahary A, Broady R, Levings MK. Inflammatory effects of ex vivo human Th17 cells are suppressed by regulatory T cells. J Immunol 2010; 185: 3199-3208 [PMID: 20720207 DOI: 10.4049/jimmunol.1000557]
89. 89 Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002; 102: 169-178 [PMID: 11846459 DOI: 10.1006/clim.2001.5163]
90. 90 Mumm JB, Oft M. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity. Bioessays 2013; 35: 623-631 [PMID:23666891 DOI: 10.1002/bies.201300004]
91. 91 Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, Weitz J, Koch M, Halverson AL, Bentrem DJ, Khazaie K. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA 2010; 107: 6430-6435 [PMID: 20308560 DOI: 10.1073/pnas.0913683107]
92. 92 Stewart CA, Metheny H, Iida N, Smith L, Hanson M, Steinhagen F, Leighty RM, Roers A, Karp CL, Müller W, Trinchieri G. Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest 2013; 123: 4859-4874 [PMID: 24216477 DOI: 10.1172/JCI65180]
93. 93 Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, Sheppard C, Hong K, Cutler C, Turner S, LaFace D, Kleinschek M, Judo M, Ayanoglu G, Langowski J, Gu D, Paporello B, Murphy E, Sriram V, Naravula S, Desai B, Medicherla S, Seghezzi W, McClanahan T, Cannon-Carlson S, Beebe AM, Oft M. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 2011; 20: 781-796 [PMID: 22172723 DOI: 10.1016/j.ccr.2011.11.003]
94. 94 Karim BO, Huso DL. Mouse models for colorectal cancer. Am J Cancer Res 2013; 3: 240-250 [PMID: 23841024]
95. 95 Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 Suppl 2: 1-5 [PMID: 12950413]
96. 96 Tseng W, Leong X, Engleman E. Orthotopic mouse model of colorectal cancer. J Vis Exp 2007; (10): 484 [PMID: 18989400 DOI: 10.3791/484]
97. 97 Terracina KP, Aoyagi T, Huang WC, Nagahashi M, Yamada A, Aoki K, Takabe K. Development of a metastatic murine colon cancer model. J Surg Res 2015 Apr 15; Epub ahead of print [PMID: 26009494 DOI: 10.1016/j.jss.2015.04.030]
98. 98 Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111: 2214-2219 [PMID: 25211661 DOI: 10.1038/bjc.2014.348]
99. 99 Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465 [PMID: 22658128 DOI: 10.1056/NEJMoa1200694]
100. 100 Callahan MK, Wolchok JD. At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013; 94: 41-53 [PMID: 23667165 DOI: 10.1189/jlb.1212631]
101. 101 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454 [PMID: 22658127 DOI: 10.1056/NEJMoa1200690]
102. 102 Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030 [PMID: 24590637 DOI: 10.1200/JCO.2013.53.0105]
103. 103 Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5: 43-51 [PMID: 25358689 DOI: 10.1158/2159-8290.CD-14-0863]
104. 104 Karlsson M, Marits P, Dahl K, Dagöö T, Enerbäck S, Thörn M, Winqvist O. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol 2010; 17: 1747-1757 [PMID: 20119674 DOI: 10.1245/s10434-010-0920-8]
105. 105 Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19: 620-626 [PMID: 21157437 DOI: 10.1038/mt.2010.272]